141 related articles for article (PubMed ID: 37321075)
1. T cell immunity in interstitial lung disease with non-small cell lung cancer patients.
Isono T; Iwahori K; Yanagawa M; Yamamoto Y; Tone M; Haruna M; Hirata M; Fukui E; Kimura T; Kanou T; Ose N; Funaki S; Takeda Y; Morii E; Kumanogoh A; Shintani Y; Wada H
Lung Cancer; 2023 Aug; 182():107278. PubMed ID: 37321075
[TBL] [Abstract][Full Text] [Related]
2. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
3. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
Kanai O; Kim YH; Demura Y; Kanai M; Ito T; Fujita K; Yoshida H; Akai M; Mio T; Hirai T
Thorac Cancer; 2018 Jul; 9(7):847-855. PubMed ID: 29782069
[TBL] [Abstract][Full Text] [Related]
7. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
[TBL] [Abstract][Full Text] [Related]
8. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
[TBL] [Abstract][Full Text] [Related]
9. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
Tasaka Y; Honda T; Nishiyama N; Tsutsui T; Saito H; Watabe H; Shimaya K; Mochizuki A; Tsuyuki S; Kawahara T; Sakakibara R; Mitsumura T; Okamoto T; Kobayashi M; Chiaki T; Yamashita T; Tsukada Y; Taki R; Jin Y; Sakashita H; Natsume I; Saitou K; Miyashita Y; Miyazaki Y
Lung Cancer; 2021 May; 155():120-126. PubMed ID: 33798901
[TBL] [Abstract][Full Text] [Related]
10. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
11. The balance between lung regulatory T cells and Th17 cells is a risk indicator for the acute exacerbation of interstitial lung disease after surgery: a case-control study.
Fukui M; Harada N; Takamochi K; Hayashi T; Matsunaga T; Hattori A; Kawagoe I; Suzuki K
BMC Pulm Med; 2023 Feb; 23(1):70. PubMed ID: 36814205
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
Suzuki Y; Karayama M; Uto T; Fujii M; Matsui T; Asada K; Kusagaya H; Kato M; Matsuda H; Matsuura S; Toyoshima M; Mori K; Ito Y; Koyauchi T; Yasui H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
J Thorac Oncol; 2020 Aug; 15(8):1317-1327. PubMed ID: 32289515
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease.
Kobayashi H; Serizawa M; Naito T; Konno H; Kojima H; Mizuno T; Isaka M; Endo M; Nagashima T; Kusuhara M; Urakami K; Ohshima K; Yamaguchi K; Ohde Y; Takahashi T
Respirology; 2020 Aug; 25(8):850-854. PubMed ID: 31694070
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Tao H; Li F; Li R; Han X; Hu Y
Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]